A detailed history of New Edge Advisors, LLC transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, New Edge Advisors, LLC holds 399 shares of BEAM stock, worth $10,090. This represents 0.0% of its overall portfolio holdings.

Number of Shares
399
Previous 399 -0.0%
Holding current value
$10,090
Previous $9,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 15, 2024

SELL
$21.22 - $32.66 $912 - $1,404
-43 Reduced 9.73%
399 $9,000
Q1 2024

May 14, 2024

BUY
$23.46 - $45.07 $1,008 - $1,938
43 Added 10.78%
442 $14,000
Q4 2023

Feb 13, 2024

SELL
$17.69 - $30.76 $70 - $123
-4 Reduced 0.99%
399 $10,000
Q2 2023

Aug 14, 2023

SELL
$29.32 - $35.99 $19,556 - $24,005
-667 Reduced 62.34%
403 $12,000
Q1 2023

May 12, 2023

SELL
$30.15 - $48.79 $9,859 - $15,954
-327 Reduced 23.41%
1,070 $32,000
Q4 2022

Feb 14, 2023

BUY
$36.73 - $51.6 $51,311 - $72,085
1,397 New
1,397 $54,000

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.78B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track New Edge Advisors, LLC Portfolio

Follow New Edge Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.